Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29102030 | 0.87 | — | — | |
| SCHEMBL160290 | 0.83 | NPC1 (0.53) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL15058848 | 0.83 | — | — | |
| Bromide SCHEMBL6317924 | 0.81 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| Methane SCHEMBL27085490 | 0.81 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL13711959 | 0.81 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL233663 | 0.81 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL3049289 | 0.79 | NPC1 (0.58) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL1266434 | 0.79 | NPC1 (0.50) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL3061596 | 0.79 | RAB9A (0.50) | NPC1RAB9AMEN1HPGDGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | claimed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | claimed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | claimed |
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2015-08-20 | — | — | US | claimed |
| EP-2405973-B1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2015-04-22 | — | — | EP | claimed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | claimed |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-03-27 | — | — | US | claimed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | claimed |
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | claimed |
| EP-2575969-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-04-10 | — | — | EP | claimed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | claimed |
| WO-2008098143-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | WO | claimed |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | claimed |
| WO-2008002820-A2 | SUBSTITUTED BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | claimed |
| WO-2008002817-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | claimed |
| US-20080004258-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | claimed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| EP-1831173-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | claimed |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | US | claimed |
| WO-2006066197-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004258-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | NPC1 437/4885RAB9A 1609/4885MEN1 1878/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | NPC1 97/4885RAB9A 2737/4885MEN1 1366/4885 |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | HRH3, HRH4, HRH1 | NPC1 267/4885RAB9A 1013/4885MEN1 1264/4885 |
| US-20080045509-A1 | SUBSTITUTED BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | NPC1 294/4885RAB9A 1073/4885MEN1 1531/4885 |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | NPC1 203/4885RAB9A 697/4885MEN1 2650/4885 |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | CCNA1, CCND3, CCND1 | NPC1 2365/4885RAB9A 686/4885MEN1 531/4885 |
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | NPC1 2123/4885RAB9A 1665/4885MEN1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.